This article first appeared on GuruFocus .
Release Date: August 19, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Lycopodium Ltd ( LYOPF ) delivered record revenue of $377.5 million, up 11% year-over-year, with NPAT of $40.2 million at the top end of guidance.
-
The company has a record level of committed work, with just under 70% of FY27 revenue guidance already secured, providing strong earnings visibility.
-
Lycopodium Ltd ( LYOPF ) is expanding its geographic diversification, highlighted by its first material full EPCM award in South America (Monera San Cristabel project in Bolivia).
-
The study pipeline has more than doubled since December, with over 90 studies currently underway, indicating a robust future project pipeline.
-
The company maintains a strong balance sheet with $106.2 million in cash and minimal debt, supporting its capital-light business model and dividend payments.
-
Management provided early FY27 guidance for revenue of $540-$580 million and NPAT of $54-$58 million, reflecting high confidence in continued growth.
Negative Points
-
Lycopodium Ltd ( LYOPF )'s revenue is heavily concentrated in Africa (58%), exposing the company to potential sovereign and execution risks in those jurisdictions.
-
The company's FY27 revenue guidance implies a significant 50% year-on-year growth, with over 30% of the target still dependent on projects that have not yet formally committed.
-
Rapid expansion in the Americas requires additional investment in office space and headcount in Toronto, Vancouver, and Lima, which could pressure short-term margins.
-
The company faces execution risks on large, complex projects like the Blackwater Phase 2 expansion, which management acknowledged will come with challenges.
-
While the study pipeline is strong, conversion to project awards is not guaranteed, with management noting that only about 70% of advanced studies typically convert to execution work.
-
The business is scaling up its workforce (from 1,400 to 1,500 employees) to meet demand, which could lead to cost overruns or inefficiencies if growth is not managed carefully.
Q & A Highlights
Q: How is Lycopodium structurally mitigating increased sovereign and execution risks as its contract mix tilts heavily towards foreign jurisdictions? Additionally, is the company achieving higher project margins to compensate for these risks, or does the complexity of international work erode any potential pricing premium? A: Peter DeLeo, Managing Director and CEO, explained that Lycopodium mitigates risk through split contracts, where a large portion of work (procurement, studies) is executed in their hubs (APAC, Americas, South Africa) and contracted with those entities, keeping earnings in stable jurisdictions. In-country work is contracted through fully compliant local entities. With over 30 years of experience in similar jurisdictions, the company leverages its expertise to price fully and deliver strong returns, without gouging clients, maintaining a long-term value approach that supports strong NPAT margins.
Q: The FY27 revenue midpoint of 560 implies 50% growth year on year. What proportion is already locked in within the 661 mil committed contracts and how much depends on projects still ramping or yet to formally commit? A: Peter DeLeo confirmed that just under 70% of the FY27 revenue guidance is already committed, which is exceptional for this early stage of the financial year. The remaining 30% is expected to be secured in the near term, with several projects in final negotiation phases, including early works on a notable project that could play out over the next 12 months.
Q: On the study pipeline, it's more than doubled since December. What's your historical conversion rate from study to project award, and how should we think about typical lead times? Also, how's the composition of these studies shifted, i.e., Americas based majors versus emerging companies or those with multi-asset? A: Peter DeLeo noted the study composition is well-diversified across geographies, commodities, and client types (from majors to juniors), with a good mix of advanced-stage DFS/BFS studies and earlier-stage work. Regarding conversion, retention through study phases is very high, and in over 70% of cases, Lycopodium converts advanced-stage studies into executable projects, though clients often bid out the larger execution work.
Q: On the Americas, it's great to see tendering underway across a handful of countries. Can you give us a sense of the tender pipeline quantum and realistic timeframe to material project award in that region? And how does a project like the Blackwater expansion help credentialize that North American team? A: Peter DeLeo stated the Americas pipeline is strong, targeting projects with CapEx between $500 million and $800 million, which suits their sweet spot for building out offices in Lima, Toronto, and Vancouver. The Blackwater Phase 2 project with Artemis is the largest undertaking in Canada, credentializing the team in full EPCM delivery and cold-weather engineering. Successful delivery could lead to long-term work with Artemis into the 2030s, including a Phase 3 concept study.
Q: You're obviously guiding to big growth in '27. Beyond expanding the workforce, is there anything else you need to invest in internally to deliver at that elevated level? Or are the investments you've made over the last few years sufficient? A: Peter DeLeo confirmed that structurally, no major investments are needed beyond office space. The company is expanding in Lima (to 110-120 people), Toronto, and Vancouver to accommodate growth. IT licenses and other costs scale with headcount and are already budgeted for, so the existing infrastructure and systems are sufficient to support the elevated delivery level.
Q: Guiding this early clearly is indicative of an elevated level of confidence comparative to prior periods. Does that confidence at this stage extend to 28 relative to how you felt a year ago? A: Peter DeLeo acknowledged FY28 is a long way out, but the market shows sustained opportunities. The company's increased addressable market (up 40%) could drive continued growth into FY28 and beyond, though it remains subject to market conditions and requires delivering on the current workload first.
Q: In terms of the resource studies, that's a pretty significant jump half on half. What drove the increased studies number? A: Peter DeLeo attributed the jump to both a buoyant market and the company's refined regional operating model. By breaking down silos and adopting a "One Lycopodium" approach, offices like Melbourne, Brisbane, and Cape Town are winning broader study work across commodities (uranium, diamonds, platinum, gold) and geographies. The Americas offices (Toronto, Vancouver, Saxum) have also picked up an impressive list of studies, showing early traction from the strategic changes.
Q: How is Lycopodium's contract mix evolving, and what does the record level of committed work and pipeline indicate for future earnings? A: Peter DeLeo highlighted that the company has a record level of committed contracts (up 59% from six months ago) and a revenue opportunity pipeline up 8%. With over 90 studies currently managed (two-fold increase), the pipeline supports future earnings. The company has provided early guidance for FY27 of revenue between $540-580 million and NPAT of $54-58 million, reflecting confidence in the strong and enduring market demand.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
